Summary
3.60 0.12(3.45%)09/13/2024
Burning Rock Biotech Ltd (BNR)
Burning Rock Biotech Ltd (BNR)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| 3.45 | -26.83 | -49.78 | -55.90 | 340.97 | 207.14 | 0.00 | -86.03 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 3.60 | |
| Open | 3.60 | |
| High | 3.92 | |
| Low | 3.55 | |
| Volume | 12,292 | |
| Change | 0.12 | |
| Change % | 3.45 | |
| Avg Volume (20 Days) | 4,896 | |
| Volume/Avg Volume (20 Days) Ratio | 2.51 | |
| 52 Week Range | 0.57 - 8.99 | |
| Price vs 52 Week High | -59.96% | |
| Price vs 52 Week Low | 531.58% | |
| Range | -23.56 | |
| Gap Up/Down | -0.27 | |
Fundamentals | ||
| Market Capitalization (Mln) | 37 | |
| EBIDTA | 0 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | 0.0000 | |
| WallStreet Target Price | 27.57 | |
| Book Value | 19.7740 | |
| Earnings Per Share | -1.0570 | |
| EPS Estimate Current Quarter | -0.2500 | |
| EPS Estimate Next Quarter | -0.2500 | |
| EPS Estimate Current Year | -0.9300 | |
| EPS Estimate Next Year | -0.7800 | |
| Diluted EPS (TTM) | -1.0570 | |
| Revenues | ||
| Profit Marging | -1.4262 | |
| Operating Marging (TTM) | -1.4227 | |
| Return on asset (TTM) | -0.1674 | |
| Return on equity (TTM) | -0.3057 | |
| Revenue TTM | 492,239,008 | |
| Revenue per share TTM | 4.7260 | |
| Quarterly Revenue Growth (YOY) | 0.0220 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | 313,922,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 0.0000 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 3.9301 | |
| Revenue Enterprise Value | 2.0951 | |
| EBITDA Enterprise Value | 0.0000 | |
| Shares | ||
| Shares Outstanding | 104,548,000 | |
| Shares Float | 45,402,169 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.00 | |
| Insider (%) | 0.14 | |
| Institutions (%) | 50.52 | |
08/22 23:59 EST - globenewswire.com
Burning Rock Reports Second Quarter 2024 Financial Results
GUANGZHOU, China, Aug. 22, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today reported financial results for the three months ended June 30, 2024. Recent Business Updates Therapy Selection Presented study results on small-cell lung cancer and colorectal cancer at the ASCO in June 2024.
Burning Rock Reports Second Quarter 2024 Financial Results
GUANGZHOU, China, Aug. 22, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today reported financial results for the three months ended June 30, 2024. Recent Business Updates Therapy Selection Presented study results on small-cell lung cancer and colorectal cancer at the ASCO in June 2024.
08/19 02:21 EST - globenewswire.com
Burning Rock Biotech Limited Announces Expected Delisting of American Depositary Shares
GUANGZHOU, China, Aug. 19, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (the “Company” or “Burning Rock”) announces that, on August 19, 2024, it intends to submit requests (a) to the London Stock Exchange (the “LSE”), to cancel the admission to trading on the Main Market of its American Depositary Shares representing the class A ordinary shares of the Company (the “ADSs”), and (b) to the UK Financial Conduct Authority, to cancel the listing of the ADSs on the Official List. As a result of sustained low volume of trading and liquidity in the ADSs on the LSE, and taking into account the costs associated with maintaining such listing in place, the Company is seeking the delisting and cancellation of admission to trading of the ADSs from the LSE (the “Delisting”).
Burning Rock Biotech Limited Announces Expected Delisting of American Depositary Shares
GUANGZHOU, China, Aug. 19, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (the “Company” or “Burning Rock”) announces that, on August 19, 2024, it intends to submit requests (a) to the London Stock Exchange (the “LSE”), to cancel the admission to trading on the Main Market of its American Depositary Shares representing the class A ordinary shares of the Company (the “ADSs”), and (b) to the UK Financial Conduct Authority, to cancel the listing of the ADSs on the Official List. As a result of sustained low volume of trading and liquidity in the ADSs on the LSE, and taking into account the costs associated with maintaining such listing in place, the Company is seeking the delisting and cancellation of admission to trading of the ADSs from the LSE (the “Delisting”).
06/03 00:41 EST - globenewswire.com
Burning Rock Regains Compliance with NASDAQ Minimum Bid Price Requirement
GUANGZHOU, China, June 03, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that it has received a notification letter from the staff of the Listing Qualifications Department of the Nasdaq Stock Market LLC (“NASDAQ”) on May 30, 2024, informing the Company that it has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Price Requirement”). As previously announced, on December 29, 2023, the Company was notified by NASDAQ that it was not in compliance with the Minimum Bid Price Requirement because the closing bid price for the Company's American depositary shares (the “ADSs”) was below the minimum bid price of $1.00 per share for 30 consecutive business days.
Burning Rock Regains Compliance with NASDAQ Minimum Bid Price Requirement
GUANGZHOU, China, June 03, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that it has received a notification letter from the staff of the Listing Qualifications Department of the Nasdaq Stock Market LLC (“NASDAQ”) on May 30, 2024, informing the Company that it has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Price Requirement”). As previously announced, on December 29, 2023, the Company was notified by NASDAQ that it was not in compliance with the Minimum Bid Price Requirement because the closing bid price for the Company's American depositary shares (the “ADSs”) was below the minimum bid price of $1.00 per share for 30 consecutive business days.
05/30 03:42 EST - globenewswire.com
Bayer and Burning Rock collaborate to increase patient access to precision cancer medicines
GUANGZHOU, China, May 30, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”) has recently announced a collaboration with Bayer to develop next-generation sequencing (NGS)-based companion diagnostic assays (CDx), aiming to provide diagnostic methods, to enable treatment choice for patients with cancer in China, while driving innovation and development in cancer therapy. This collaboration will focus on the development of companion diagnostic products in China, jointly developing NGS-based CDx for Bayer's growing portfolio of precision cancer therapies.
Bayer and Burning Rock collaborate to increase patient access to precision cancer medicines
GUANGZHOU, China, May 30, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”) has recently announced a collaboration with Bayer to develop next-generation sequencing (NGS)-based companion diagnostic assays (CDx), aiming to provide diagnostic methods, to enable treatment choice for patients with cancer in China, while driving innovation and development in cancer therapy. This collaboration will focus on the development of companion diagnostic products in China, jointly developing NGS-based CDx for Bayer's growing portfolio of precision cancer therapies.
05/29 01:34 EST - globenewswire.com
Burning Rock Reports First Quarter 2024 Financial Results
GUANGZHOU, China, May 29, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today reported financial results for the three months ended March 31, 2024. Recent Business Updates Early Detection THUNDER study for 6-cancer test was included in the Diagnosis and Treatment Guidelines for Primary Liver Cancer (2024 Edition) and the Expert Consensus on Detection and Clinical Application of Tumor DNA Methylation Markers (2024 Edition), showing an impressive performance of ELSA-seq using cfDNA in cancer detection and origin prediction.
Burning Rock Reports First Quarter 2024 Financial Results
GUANGZHOU, China, May 29, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today reported financial results for the three months ended March 31, 2024. Recent Business Updates Early Detection THUNDER study for 6-cancer test was included in the Diagnosis and Treatment Guidelines for Primary Liver Cancer (2024 Edition) and the Expert Consensus on Detection and Clinical Application of Tumor DNA Methylation Markers (2024 Edition), showing an impressive performance of ELSA-seq using cfDNA in cancer detection and origin prediction.
05/23 02:00 EST - globenewswire.com
Burning Rock Schedules First Quarter of 2024 Earnings Release on May 29, 2024
GUANGZHOU, China, May 23, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that it plans to release its unaudited financial results for the first quarter of 2024 before the U.S. market opens on May 29, 2024. Following the release, company management will host a conference call at 8:00 a.m.
Burning Rock Schedules First Quarter of 2024 Earnings Release on May 29, 2024
GUANGZHOU, China, May 23, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that it plans to release its unaudited financial results for the first quarter of 2024 before the U.S. market opens on May 29, 2024. Following the release, company management will host a conference call at 8:00 a.m.
05/14 02:02 EST - globenewswire.com
Burning Rock Announces ADS Ratio Change to Be Effective on May 15, 2024
GUANGZHOU, China, May 14, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that, as previously announced on April 26, 2024, the ratio change of its American depositary shares (the “ADSs”) to Class A ordinary shares from one (1) ADS representing one (1) Class A ordinary share to one (1) ADS representing ten (10) Class A ordinary shares (the “ADS Ratio Change”) will become effective on May 15, 2024 (the “Effective Date”). For Burning Rock's ADS holders, the ADS Ratio Change will have the same effect as a one-for-ten reverse ADS split.
Burning Rock Announces ADS Ratio Change to Be Effective on May 15, 2024
GUANGZHOU, China, May 14, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that, as previously announced on April 26, 2024, the ratio change of its American depositary shares (the “ADSs”) to Class A ordinary shares from one (1) ADS representing one (1) Class A ordinary share to one (1) ADS representing ten (10) Class A ordinary shares (the “ADS Ratio Change”) will become effective on May 15, 2024 (the “Effective Date”). For Burning Rock's ADS holders, the ADS Ratio Change will have the same effect as a one-for-ten reverse ADS split.
04/29 03:30 EST - globenewswire.com
Burning Rock Publishes 2023 Annual Report on Form 20-F
GUANGZHOU, China, April 29, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing technology in the field of precision oncology, announces that on April 29, 2024 it filed its Annual Report on Form 20-F for the year ended December 31, 2023 (the “Form 20-F”) with the U.S. Securities and Exchange Commission (“SEC”). The Form 20-F is available for viewing on the SEC website at www.sec.gov and also on the Company's website at http://ir.brbiotech.com.
Burning Rock Publishes 2023 Annual Report on Form 20-F
GUANGZHOU, China, April 29, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing technology in the field of precision oncology, announces that on April 29, 2024 it filed its Annual Report on Form 20-F for the year ended December 31, 2023 (the “Form 20-F”) with the U.S. Securities and Exchange Commission (“SEC”). The Form 20-F is available for viewing on the SEC website at www.sec.gov and also on the Company's website at http://ir.brbiotech.com.
04/26 01:59 EST - globenewswire.com
Burning Rock Announces ADS Ratio Change
GUANGZHOU, China, April 26, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that it will change the ratio of its American depositary shares (the “ADSs”) to Class A ordinary shares from one (1) ADS representing one (1) Class A ordinary share to one (1) ADS representing ten (10) Class A ordinary shares (the “ADS Ratio Change”). The ADS Ratio Change is expected to become effective on or about May 15, 2024 (the “Effective Date”).
Burning Rock Announces ADS Ratio Change
GUANGZHOU, China, April 26, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that it will change the ratio of its American depositary shares (the “ADSs”) to Class A ordinary shares from one (1) ADS representing one (1) Class A ordinary share to one (1) ADS representing ten (10) Class A ordinary shares (the “ADS Ratio Change”). The ADS Ratio Change is expected to become effective on or about May 15, 2024 (the “Effective Date”).
03/28 17:16 EST - globenewswire.com
Burning Rock Reports Fourth Quarter and Full Year 2023 Financial Results
GUANGZHOU, China, March 28, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today reported financial results for the three months and the year ended December 31, 2023. 2023 Business Overview and Recent Updates Corporate Updates Completed profitability-driven organizational optimization, execution towards profitability well underway Early Detection Following the Breakthrough Device Designation granted by the US Food and Drug Administration (FDA) for our OverC™ Multi-Cancer Detection Blood Test (MCDBT) in January 2023, our OverC™ MCDBT also received the Breakthrough Device Designation by China's National Medical Products Administration (NMPA) in October 2023, making it the only test globally that has received Breakthrough Device Designation from both the FDA and the NMPA.
Burning Rock Reports Fourth Quarter and Full Year 2023 Financial Results
GUANGZHOU, China, March 28, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today reported financial results for the three months and the year ended December 31, 2023. 2023 Business Overview and Recent Updates Corporate Updates Completed profitability-driven organizational optimization, execution towards profitability well underway Early Detection Following the Breakthrough Device Designation granted by the US Food and Drug Administration (FDA) for our OverC™ Multi-Cancer Detection Blood Test (MCDBT) in January 2023, our OverC™ MCDBT also received the Breakthrough Device Designation by China's National Medical Products Administration (NMPA) in October 2023, making it the only test globally that has received Breakthrough Device Designation from both the FDA and the NMPA.
01/04 01:03 EST - globenewswire.com
Burning Rock Announces Receipt of Notification from NASDAQ
GUANGZHOU, China, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that it has received written notification from the staff of the Listing Qualifications Department of the Nasdaq Stock Market LLC (“NASDAQ”) dated December 29, 2023, indicating that for the last 30 consecutive business days, the closing bid price for the Company's American depositary shares (the “ADSs”) was below the minimum bid price of US$1.00 per share requirement set forth in NASDAQ Listing Rule 5450(a)(1). The NASDAQ notification letter has no current effect on the listing or trading of the Company's securities on NASDAQ.
Burning Rock Announces Receipt of Notification from NASDAQ
GUANGZHOU, China, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that it has received written notification from the staff of the Listing Qualifications Department of the Nasdaq Stock Market LLC (“NASDAQ”) dated December 29, 2023, indicating that for the last 30 consecutive business days, the closing bid price for the Company's American depositary shares (the “ADSs”) was below the minimum bid price of US$1.00 per share requirement set forth in NASDAQ Listing Rule 5450(a)(1). The NASDAQ notification letter has no current effect on the listing or trading of the Company's securities on NASDAQ.
12/19 21:35 EST - globenewswire.com
Burning Rock Announces Results of 2023 Annual General Meeting
GUANGZHOU, China, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”), a company focusing on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that all shareholder resolutions proposed at the Company's 2023 annual general meeting held today were duly passed. Specifically, the shareholders passed the following resolutions: To ratify the appointment of Ernst & Young Hua Ming LLP as auditor of the Company for the fiscal year ending December 31, 2023 and to authorize the directors of the Company to determine the remuneration of the auditor; To re-elect Wendy Hayes, Min-Jui Richard Shen and Zhihong (Joe) Zhang as directors of the Company; and To authorize each of the directors of the Company to take any and all action that might be necessary to effect the foregoing resolutions as such director, in his or her absolute discretion, thinks fit.
Burning Rock Announces Results of 2023 Annual General Meeting
GUANGZHOU, China, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”), a company focusing on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that all shareholder resolutions proposed at the Company's 2023 annual general meeting held today were duly passed. Specifically, the shareholders passed the following resolutions: To ratify the appointment of Ernst & Young Hua Ming LLP as auditor of the Company for the fiscal year ending December 31, 2023 and to authorize the directors of the Company to determine the remuneration of the auditor; To re-elect Wendy Hayes, Min-Jui Richard Shen and Zhihong (Joe) Zhang as directors of the Company; and To authorize each of the directors of the Company to take any and all action that might be necessary to effect the foregoing resolutions as such director, in his or her absolute discretion, thinks fit.
11/30 09:26 EST - seekingalpha.com
Burning Rock Biotech Limited (BNR) Q3 2023 Earnings Call Transcript
Burning Rock Biotech Limited (NASDAQ:BNR ) Q3 2023 Earnings Call Transcript November 30, 2023 7:00 AM ET Company Participants Yusheng Han - Founder, Chairman and Chief Executive Officer Leo Li - CFO Joe Zhang - CTO Conference Call Participants Operator Before we begin, I would like to remind you that this conference call contains forward-looking statements within the meaning of the Section 21E of the Securities Exchange Act of 1934 as amended and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as will, expect, anticipate, future, intends, plans, believes, estimates, target, confident and similar statements.
Burning Rock Biotech Limited (BNR) Q3 2023 Earnings Call Transcript
Burning Rock Biotech Limited (NASDAQ:BNR ) Q3 2023 Earnings Call Transcript November 30, 2023 7:00 AM ET Company Participants Yusheng Han - Founder, Chairman and Chief Executive Officer Leo Li - CFO Joe Zhang - CTO Conference Call Participants Operator Before we begin, I would like to remind you that this conference call contains forward-looking statements within the meaning of the Section 21E of the Securities Exchange Act of 1934 as amended and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as will, expect, anticipate, future, intends, plans, believes, estimates, target, confident and similar statements.
11/30 01:25 EST - globenewswire.com
Burning Rock Reports Third Quarter 2023 Financial Results
GUANGZHOU, China, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today reported financial results for the three months ended September 30, 2023. Recent Business Updates Therapy Selection and Minimal Residual Disease (MRD) Personalized Minimal Residual Disease (MRD) product, brPROPHETTM supports advancement in early-stage non-small cell lung cancer treatment, with results published in the Cancer Cell in September 2023.
Burning Rock Reports Third Quarter 2023 Financial Results
GUANGZHOU, China, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today reported financial results for the three months ended September 30, 2023. Recent Business Updates Therapy Selection and Minimal Residual Disease (MRD) Personalized Minimal Residual Disease (MRD) product, brPROPHETTM supports advancement in early-stage non-small cell lung cancer treatment, with results published in the Cancer Cell in September 2023.
11/22 02:04 EST - globenewswire.com
Burning Rock Announces 2023 Annual General Meeting to be Held on December 20, 2023
GUANGZHOU, China, Nov. 22, 2023 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”), a company focusing on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that it will hold its annual general meeting (“AGM”) on December 20, 2023 at 10:00 a.m. (local time) at the Company's Shanghai office at 6/F, Building 10C, Pujiang Smart Plaza, No.
Burning Rock Announces 2023 Annual General Meeting to be Held on December 20, 2023
GUANGZHOU, China, Nov. 22, 2023 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”), a company focusing on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that it will hold its annual general meeting (“AGM”) on December 20, 2023 at 10:00 a.m. (local time) at the Company's Shanghai office at 6/F, Building 10C, Pujiang Smart Plaza, No.
11/20 20:55 EST - globenewswire.com
Burning Rock Schedules Third Quarter of 2023 Earnings Release on November 30, 2023
GUANGZHOU, China, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that it plans to release its unaudited financial results for the third quarter of 2023 before the U.S. market opens on November 30, 2023. Following the release, company management will host a conference call at 7:00 a.m.
Burning Rock Schedules Third Quarter of 2023 Earnings Release on November 30, 2023
GUANGZHOU, China, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that it plans to release its unaudited financial results for the third quarter of 2023 before the U.S. market opens on November 30, 2023. Following the release, company management will host a conference call at 7:00 a.m.
10/30 03:20 EST - globenewswire.com
Burning Rock and Boehringer Ingelheim Achieved a Master Service Agreement in Oncology Companion Diagnostics
GUANGZHOU, China, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”) is pleased to announce that the Company and Boehringer Ingelheim officially have signed the Master Service Agreement (MSA) in the field of oncology companion diagnostics. This agreement aims to provide Chinese patients with safer, more efficient, and precise treatment options and diagnostic methods, thereby promoting innovation and development in cancer treatment.
Burning Rock and Boehringer Ingelheim Achieved a Master Service Agreement in Oncology Companion Diagnostics
GUANGZHOU, China, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”) is pleased to announce that the Company and Boehringer Ingelheim officially have signed the Master Service Agreement (MSA) in the field of oncology companion diagnostics. This agreement aims to provide Chinese patients with safer, more efficient, and precise treatment options and diagnostic methods, thereby promoting innovation and development in cancer treatment.
10/15 19:18 EST - globenewswire.com
Burning Rock Received Breakthrough Device Designation from China's NMPA for its Multi-Cancer Early Detection Test
GUANGZHOU, China, Oct. 15, 2023 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”) is pleased to announce that followed an earlier Breakthrough Device Designation granted by the US Food and Drug Administration (FDA) for its OverC™ Multi-Cancer Detection Blood Test (MCDBT) in January 2023, its OverC™ MCDBT has been granted Breakthrough Device Designation by the China National Medical Products Administration(NMPA), which represents the only test globally that has received Breakthrough Device Designation from both US FDA and China NMPA. OverC™ MCDBT is intended for early detection of multiple cancer types in adults of either sex, aged 50-75 years old, at average risk for cancer.
Burning Rock Received Breakthrough Device Designation from China's NMPA for its Multi-Cancer Early Detection Test
GUANGZHOU, China, Oct. 15, 2023 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”) is pleased to announce that followed an earlier Breakthrough Device Designation granted by the US Food and Drug Administration (FDA) for its OverC™ Multi-Cancer Detection Blood Test (MCDBT) in January 2023, its OverC™ MCDBT has been granted Breakthrough Device Designation by the China National Medical Products Administration(NMPA), which represents the only test globally that has received Breakthrough Device Designation from both US FDA and China NMPA. OverC™ MCDBT is intended for early detection of multiple cancer types in adults of either sex, aged 50-75 years old, at average risk for cancer.
09/07 22:43 EST - globenewswire.com
Burning Rock's minimal residual disease (MRD) product supports advancement in early-stage non-small cell lung cancer treatment, with results published in the Cancer Cell
GUANGZHOU, China, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”) is delighted to announce that our personalized Minimal Residual Disease (MRD) product, CanCatch® (PROPHETTM panel), was enrolled in a prospective observational study (MEDAL, MEthylation based Dynamic Analysis for Lung cancer, NCT03634826).
Burning Rock's minimal residual disease (MRD) product supports advancement in early-stage non-small cell lung cancer treatment, with results published in the Cancer Cell
GUANGZHOU, China, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”) is delighted to announce that our personalized Minimal Residual Disease (MRD) product, CanCatch® (PROPHETTM panel), was enrolled in a prospective observational study (MEDAL, MEthylation based Dynamic Analysis for Lung cancer, NCT03634826).
08/31 15:12 EST - seekingalpha.com
Burning Rock Biotech Limited (BNR) Q2 2023 Earnings Call Transcript
Burning Rock Biotech Limited (NASDAQ:BNR ) Q2 2023 Earnings Conference Call August 31, 2023 8:00 AM ET Company Participants Yusheng Han - Founder, Chairman and CEO Leo Li - CFO Conference Call Participants Operator Good morning, ladies and gentlemen. Thank you for standing by.
Burning Rock Biotech Limited (BNR) Q2 2023 Earnings Call Transcript
Burning Rock Biotech Limited (NASDAQ:BNR ) Q2 2023 Earnings Conference Call August 31, 2023 8:00 AM ET Company Participants Yusheng Han - Founder, Chairman and CEO Leo Li - CFO Conference Call Participants Operator Good morning, ladies and gentlemen. Thank you for standing by.